Basal cell carcinoma in a breast-Clinical and genetic characterization of basal cell carcinoma and breast cancer in a single patient

What is Basal Cell Carcinoma? Basal cell carcinoma BCC is the most common type of skin cancer. It starts in the top layer of the skin called the epidermis. Most of the time, BCC can be removed and treated. But sometimes it can grow back.

Basal cell carcinoma in a breast

Basal cell carcinoma in a breast

Basal cell carcinoma in a breast

The tumor with histological degree II, showed accentuated formation of tubules, moderate mitotic index, macroscopic metastasis in Basal cell carcinoma in a breast nodes, angio lymphatic invasion and infiltration of the skin. Deletions at the end of celll arms of one allele 6 are often involved in this rare de novo event. Small supernumerary marker chromosomes and also ring chromosomes have been found in several instances as derived from chromosome 6 Huang et al. By continuing, you agree to the use of cookies as stated in our Privacy Policy. Cancer establishment depends on multistep alterations of the genome including Mime fucking mutations, deletions or insertions, and epigenetics inn, leading to decreased apoptosis, increased cell proliferation, angiogenesis, invasion and metastasis. The POSTN gene encodes the osteoblast specific factor periostin that is associated with cellular adhesion; it is expressed in normal breast tissue, cacrinoma is up regulated in breast cancer Zhang et al.

Adult torrent books. Related News

About Basal Cell Carcinoma Basal cell carcinoma is the most common form of cancer worldwide. Avoiding the sun and using sunscreen may help protect against basal cell carcinoma. Second, the inclusion criteria of theorical basal tumors, which use the imperfect TN definition, led in fact to the enrollment of basal and non-basal tumors very different at the histoclinical level, but also for the RNA expression of the theorical therapeutic target [ 22 ]. Skin cancer begins in the cells that make up the outer layer epidermis of your skin. Ann Saudi Med. Don't forget sunglasses. The frequent triple-negativity of Basal cell carcinoma in a breast breast cancers does not render them candidate to hormone therapy and anti-ERBB2 therapies, and until now, chemotherapy represented the sole available systemic treatment. Tracy schultz Cell. Most of trials are ongoing, and many others will be soon activated in the metastatic, neo-adjuvant and also adjuvant settings. These treatments are sometimes options for treating very superficial tumors tumors that have not grown too deeply into the skin. Gusterson B. It also feels like a spongy area of breast tissue. Metastatic Basal cell carcinoma in a breast Cancer will have begun in the breast and then spreads to distant parts of the Ree bdsm. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.

Several types of treatment can be used to remove or destroy basal cell skin cancers.

  • Basal cell carcinoma BCC of the breast is a rare occurrence.
  • Several types of treatment can be used to remove or destroy basal cell skin cancers.
  • There are several types of breast cancer, and they differ from each other.
  • During the last decade, gene expression profiling of breast cancer has revealed the existence of five molecular subtypes and allowed the establishment of a new classification.

What is Basal Cell Carcinoma? Basal cell carcinoma BCC is the most common type of skin cancer. It starts in the top layer of the skin called the epidermis. Most of the time, BCC can be removed and treated. But sometimes it can grow back. Most BCCs show up on sun-exposed areas of the body, especially the face and neck.

But they can occur in other areas too. Certain people are more likely to have skin cancer. For example, people with fair skin, light-colored eyes or blond or red hair are especially prone to developing basal cell carcinoma BCC. Regardless of what it looks like, if you notice something on your skin that worries you, or if an existing growth starts to change or irritate you, get it checked out. Try to do regular skin exams too. Your doctor will examine your skin. A biopsy is typically needed to confirm a diagnosis of skin cancer.

A biopsy is a common procedure to remove a piece of the skin. Then the doctor often a dermatologist or skin doctor will cut a small piece of the skin to get a sample of tissue. A different doctor called a pathologist, often a dermatopathologist will look at this tissue under the microscope to check for cancer cells.

There are several types of biopsies. BCC usually grows slowly. In some cases, especially if it is untreated, it can invade nearby tissue. However, it is very rare for BCC to metastasize and lead to death. In the majority of cases, Basal Cell Carcinoma is easily cured using local surgery or medications applied to the skin called topical therapies Rarely, radiation can be used. Treatment will depend on where it is located, how big and deep the tumor is in the skin, and if local lymph nodes are involved.

Additional treatment options are available for people with later stage disease. Learn More. Fortunately, most BCCs are found early and cured. Still, it is very important to pay attention to sun safety. Avoid being in the sun during peak daylight hours, always apply and reapply sunscreen and wear protective clothing, sunglasses and wide-brimmed hats.

Talk to your family and friends about the importance of skin cancer prevention too. Be sure to see your dermatologist regularly for skin exams. Pay close attention to any sores or bumps that might develop on your skin.

Often, you first notice BCC as a lesion on the skin that you think should heal in a week or two. However, one month later it is still there, getting red, raw, and irritated. If lesions do not resolve on their own, they need to be examined by a board-certified dermatologist. Providing professional programs of emotional support, education and hope for people impacted by cancer at no charge so that no one faces cancer alone.

Cancer Support Community uses cookies to personalize your experience. By continuing, you agree to the use of cookies as stated in our Privacy Policy.

Skip to main content. Search this site. Learn About Cancer. Cancer Types. Cancer Topics. Find Support. Cancer Support Helpline. Online Cancer Support. Other Support Topics. Living With Cancer. Living With Cancer Topics. Cancer Diagnosis?

Make a Difference. Our Research. Cancer Experience Registry. Action Center. Become an Advocate Cancer Moonshot Initiative. About Us. Careers Contact Us. Is Immunotherapy Right For You? Why are Biosimilars important?

Should I Join a Support Group? Basal Cell Carcinoma. Risk Factors Certain people are more likely to have skin cancer. How soon will I know the results? Will there be a lot of scarring? What is the plan if it is cancerous malignant? What treatment is most likely to work? How likely is it that it will return?

What should I be doing to prevent skin cancer from coming back? Share Tweet Share Share Forward. Subscribe Organization. Bradley foundation. Bristol-Myers Squibb. EMD Serono. Genentech Biooncology. Jazz Pharmaceuticals. Lilly Oncology. Novartis Oncology. Pfizer Oncology. Live Web Chat Available during call center hours. Got it!

An exploratory analysis suggested that patients who received iniparib as second- or third-line therapy might have benefited from treatment, Another PARP inhibitor, veliparib, given in combination with temozolomide in a phase II trial of metastatic breast cancer patients showed that responses were limited to BRCA-associated cases [ ], further suggesting the need for proper patient selection. Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Promising results were initially reported with iniparib BSI and olaparib. These basal cells are thought to be immature progenitors and stem cells. Metastatic Breast Cancer. Repeated observation of breast tumor subtypes in independent gene expression data sets.

Basal cell carcinoma in a breast

Basal cell carcinoma in a breast. Signs and Symptoms of Basal Cell Carcinoma

Metastatic Breast Cancer is considered a stage 4 breast cancer, treatable but not curable. In addition to chemotherapy, radiation therapy, and hormone therapy, women with metastatic breast cancer may choose to explore the possibility of participating in clinical trials for emerging treatments. Unfortunately, many information sources about breast cancer that can be found on the web do not clarify that breast cancer has many subtypes and that not all subtypes present as a lump.

Get honest information, the latest research, and support for you or a loved one with breast cancer right to your inbox.

American Cancer Society. Breast Pathology. Inflammatory Breast Cancer. Cancer Treatment Centers of America. Rare breast cancer types. Metastatic Breast Cancer. More in Breast Cancer. Medullary Carcinoma , which usually can be seen on a mammogram, can at times feel spongy to the touch, not like a lump.

It also feels like a spongy area of breast tissue. This cancer is most often found in women over 50 years of age. Cells are poorly defined with mucus production. Was this page helpful? Thanks for your feedback! Sign Up. What are your concerns? Article Sources. Breast Pathology American Cancer Society.

Rare breast cancer types BreastCancer. Metastatic Breast Cancer Breastcancer. The color legend is similar to Fig. Although the discrepancies reported across studies regarding the prognosis and the response to chemotherapy may reflect differences in treatments and populations, they may also reflect the heterogeneity of basal breast cancers. Not all patients have an unfavorable clinical outcome. To date, reliable identification of basal breast cancer patients with a good or a poor prognosis is difficult and based only using histoclinical features, which are far from being optimal [ - ].

But these reported prognostic studies have so far concerned basal tumors defined using the TN definition only. We [ 39 ] and others [ 30 , ] showed that the basal subtype was associated with poor survival within TN cancer women.

In this subgroup, the major prognostic factor was an immune response module, the expression of which is associated with better survival. In two studies dedicated to basal tumors only, we confirmed the favorable prognostic impact of activation of cytotoxic tumor-infiltrative lymphocytes [ , ]. Few data exist regarding the association of basal subtype with the rate of loco-regional recurrence. Some groups have reported the absence of differences with the other subtypes IHC definition [ 98 , ].

The frequent triple-negativity of basal breast cancers does not render them candidate to hormone therapy and anti-ERBB2 therapies, and until now, chemotherapy represented the sole available systemic treatment.

However, the recent insights in the pathogenesis of these tumors are being translated into the development of new therapeutic strategies targeting molecular alterations Fig. Clinical trials are underway, which undoubtedly, will contribute to enlarge our therapeutic armamentarium in a near future. We present here some promising research directions for more exhaustive reviews, see [ , ].

The first strategies exploit the defect in double-strand DNA break repair mechanisms. Regarding chemotherapy, this defect should confer sensitivity to certain drugs [ 63 , ], notably the DNA-damaging agents like platinum compounds [ ], mitomycin-C [ ], anthracyclines, etoposide and bleomycin.

To date, a few clinical data, if any, support these in vitro observations. That was confirmed in a retrospective study, which revealed that such tumors are more sensitive to platinum compounds than to non-platinum-based regimens [ ]. Another promising alkylating agent is trabectedin [ ]. Several other drugs, such as taxanes, gemcitabine, and metronomic chemotherapy, are under evaluation. This enzyme is critical in the base excision repair of single-strand DNA breaks. In its absence, single-strand breaks degenerate to double-strand breaks, which are not repaired if BRCA1 is deficient [ ].

Several PARP1 inhibitors iniparib, olaparib, and veliparib , alone as agent causing synthetic lethality or in combination with chemotherapy as chemopotentiating agent , are in clinical development in patients with TN or BRCA1 -associated breast cancers. Promising results were initially reported with iniparib BSI and olaparib. However, these results did not hold up in the following phase III trial that enrolled TN patents pretreated with two or fewer metastatic regimens [ ].

All patients received gemcitabine and carboplatin and were randomized to iniparib or placebo. The one-month improvement in PFS median: 4. An exploratory analysis suggested that patients who received iniparib as second- or third-line therapy might have benefited from treatment, Another PARP inhibitor, veliparib, given in combination with temozolomide in a phase II trial of metastatic breast cancer patients showed that responses were limited to BRCA-associated cases [ ], further suggesting the need for proper patient selection.

Anti-angiogenic agents are under evaluation in TN breast cancers. In the ECOG trial, which compared weekly paclitaxel with and without bevacizumab, a monoclonal antibody directed against VEGF, TN patients benefited from bevacizumab as much as the average [ ]. Two studies assessing sorefenib in the metastatic setting gave discordant results regarding the benefit in the TN subgroup [ , ]. Bevacizumab is being tested in the neo-adjuvant CALGB trial, which includes a second randomization with vs.

Several other potential targets for TN tumors are involved in signal transduction pathways. Another completed phase II trial compared irinotecan plus carboplatin with versus without cetuximab [ ]: the response rate was higher with the antibody 49 vs. The high failure rate with EGFR inhibitors relatively to the frequent overexpression may be due to the absence of pathway activation EGFR gene amplification is rare or the existence of alternative activation pathways such as the frequently observed PTEN inactivation and AKT activation in TN breast cancers.

Other inhibitors of signal transduction under development target second messengers. Indeed, the frequent mTOR activation observed in TN breast cancers, and the fact that mTOR activation has been associated with cisplatinum resistance, which can be overcome with mTOR inhibitors [ ], argue for the ongoing development of everolimus in TN breast cancer, alone and in combination with cisplatinum-based regimen. Regarding dasatinib, pre-clinical data have shown that basal breast cancer cell lines are particularly sensitive to this inhibitor [ , ].

In a phase II trial of single-agent dasatinib in pretreated metastatic TN patients, the response rate was low 4. Finally, the favorable prognostic impact of the lymphocyte activation in basal breast cancer and the identification of new antigens suggest that strategies aimed at stimulating the immune system should be tested.

Identification of protein networks and pathways that control breast cancer stem cells should also help design new drugs. Most of trials are ongoing, and many others will be soon activated in the metastatic, neo-adjuvant and also adjuvant settings.

Given the results of the first completed trials, caution is required for the interpretation of the results and the selection of patients in future trials for at least two reasons. First, initial studies were not directed specifically at TN breast cancers but at all breast cancers, arising the issue of unplanned subset analyses that often do not have the statistical power to detect significant differences.

Second, the inclusion criteria of theorical basal tumors, which use the imperfect TN definition, led in fact to the enrollment of basal and non-basal tumors very different at the histoclinical level, but also for the RNA expression of the theorical therapeutic target [ 22 ].

Ideally, the development of a companion molecular test for better selecting the patients should be associated to better understand the impact of the drug. In this context a retrospective evaluation of basal markers and the search for companion markers will have to be done, notably in the negative or non-significant trials to attempt to document a positive impact in the basal population or the marker-positive subset, provided that tissue samples have been collected prospectively.

Genomics has modified our view of breast cancer, which is currently considered as a group of molecularly distinct diseases. The basal subtype represents a challenging subtype with distinctive epidemiological, histoclinical, and molecular features, with distinctive patterns of relapse, poor prognosis despite relative chemosensitivity, and no available targeted therapy.

A detailed molecular characterization of basal tumors is ongoing, both to better understand their different biology and clinical outcome, and to identify specific diagnostic, prognostic, and therapeutic targets. National Center for Biotechnology Information , U. Current Molecular Medicine. Bentham Science Publishers. Curr Mol Med. Published online Jan. Author information Article notes Copyright and License information Disclaimer.

This article has been cited by other articles in PMC. Abstract During the last decade, gene expression profiling of breast cancer has revealed the existence of five molecular subtypes and allowed the establishment of a new classification. Keywords: Basal breast cancer, DNA microarrays, prognosis, triple-negative. Open in a separate window. Whole-genome clustering and molecular subtypes.

Overlap between basal breast cancers and TN tumors. Table 1. Survival according to molecular subtypes. Gene expression profiling of cancer by use of DNA arrays: how far from the clinic? Lancet Oncol. Sotiriou C, Piccart MJ. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?

Nat Rev Cancer. Gene expression profiling and clinical outcome in breast cancer. Molecular portraits of human breast tumours. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Basal and luminal breast cancers: basic or luminous? Int J Oncol. Repeated observation of breast tumor subtypes in independent gene expression data sets.

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study.

Clin Cancer Res. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Discovery and validation of breast cancer subtypes. Breast cancer molecular subtypes respond differently to preoperative chemotherapy.

Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res. Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling. Breast Cancer Res Treat. Conservation of breast cancer molecular subtypes and transcriptional patterns of tumor progression across distinct ethnic populations. Classification of ductal carcinoma in situ by gene expression profiling.

Breast Cancer Res. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Triple-negative breast cancer: therapeutic options. How basal are triple-negative breast cancers? Int J Cancer. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features.

Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Perou CM. Molecular stratification of triple-negative breast cancers. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer.

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Basal-like breast cancer: a critical review. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer.

Expression of epidermal growth factor receptor in relation to BRCA1 status, basal-like markers and prognosis in breast cancer. J Clin Pathol. Gene expression profiling of breast cell lines identifies potential new basal markers. Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype.

Br J Cancer. Analysis of integrin beta4 expression in human breast cancer: association with basal-like tumors and prognostic significance. AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. Moesin expression is a marker of basal breast carcinomas. How different are luminal A and basal breast cancers? Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array.

Integrated profiling of basal and luminal breast cancers. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis.

Lab Invest. Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers. Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors.

The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. X chromosomal abnormalities in basal-like human breast cancer.

Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patients.

The influence of basal phenotype on the metastatic pattern of breast cancer. Clin Oncol R Coll Radiol ; 20 —5. BRCA1 dysfunction in sporadic basal-like breast cancer. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer.

Expanding the criteria for BRCA mutation testing in breast cancer survivors. BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Genes Chromosomes Canc. BRCA1 inhibition of estrogen receptor signaling in transfected cells.

Foulkes WD. BRCA1 functions as a breast stem cell regulator. J Med Genet. Depletion of BRCA1 impairs differentiation but enhances proliferation of mammary epithelial cells. The role of BRCA1 in the cellular response to chemotherapy. Interactions with fibroblasts are distinct in Basal-like and luminal breast cancers.

Mol Cancer Res. Gusterson B. Do 'basal-like' breast cancers really exist? Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Trends Endocrinol Metab. Purification and unique properties of mammary epithelial stem cells. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med. A gene signature in breast cancer. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers.

Nat Med. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells.

Cell Stem Cell. Cancer stem cells in breast: current opinion and future challenges. ZNF gene amplification at 8p12 specifies luminal B breast cancer. Hum Pathol. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev. Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes? Descriptive analysis of estrogen receptor ER -negative, progesterone receptor PR -negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry.

Intrinsic molecular signature of breast cancer in a population-based cohort of patients. Differences in breast carcinoma characteristics in newly diagnosed African- American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Population differences in breast cancer: survey in indigenous African Women Reveals over-representation of triple-negative breast cancer. Triple-negative breast cancers are increased in black women regardless of age or body mass index.

Epidemiology of basal-like breast cancer. Genome-wide association study identifies novel breast cancer susceptibility loci. Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet. Garcia-Closas M, Chanock S. Genetic susceptibility loci for breast cancer by estrogen receptor status.

Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet. In vitro and in vivo analysis of B-Myb in basal-like breast cancer. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol. Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile.

Identification of a basal-like subtype of breast ductal carcinoma in situ. P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ. Virchows Arch. Relationship between nuclear grade of ductal carcinoma in situ and cell origin markers.

Ann Clin Lab Sci. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. J Pathol. Fadare O, Tavassoli FA. The phenotypic spectrum of basal-like breast cancers: a critical appraisal. Adv Anat Pathol. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors.

Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Basal-like breast carcinomas: clinical outcome and response to chemotherapy. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.

J Cancer Res Clin Oncol. Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study.

Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neoadjuvant chemotherapy trials. Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials.

Ann Oncol.

Basal Cell Carcinoma | Cancer Support Community

Many breast cancer cells have receptors for estrogen or progesterone. Most triple-negative breast cancers are invasive ductal carcinoma. Ductal carcinoma in situ DCIS may also be triple negative.

Most basal-like breast cancers are invasive ductal carcinomas. It is important to note that not all triple-negative breast cancers are basal-like. And not all basal-like breast cancers are triple negative. They are 2 similar, but distinct, subtypes of breast cancer. Scientists have not yet developed one internationally accepted definition of a basal-like breast cancer. But they know that it is different from other types of breast cancer.

Women under the age of 40 and women of African or Asian ancestry have a higher risk of developing triple-negative breast cancer. Basal-like breast cancers are more likely to be found in younger women and in women of African ancestry. Many triple-negative and basal-like breast cancers may be called interval cancers because they can develop between regularly scheduled screening mammography.

Most triple-negative and basal-like breast cancers are high-grade, or aggressive, tumours. This means that they tend to grow and spread quickly. Many are diagnosed at a later stage when the cancer has already spread metastasized to lymph nodes or other organs.

They do not spread to the lymph nodes or the bones as often as other types of breast cancer. Triple-negative breast cancer usually responds to chemotherapy. However, it does have a higher risk of coming back recurrence within 5 years of treatment, compared to breast cancer that is hormone-receptor positive or HER-2 positive. After 5 years, this risk decreases.

When you are diagnosed with breast cancer, your healthcare team will do certain tests to help them develop a treatment plan for you. They use hormone receptor status testing to see if the breast cancer cells have receptors for the hormones estrogen and progesterone.

Find out more about hormone receptor status testing , HER2 status testing and mammography. If you have triple-negative or basal-like breast cancer, your healthcare team will create a treatment plan just for you. It will be based on your health and specific information about the cancer. Surgery is often used to treat triple-negative and basal-like breast cancer.

The type of surgery done will depend on the type of tumour, the size of the tumour, where the cancer has spread and other factors. Chemotherapy is used to treat triple-negative and basal-like breast cancer. Cisplatin Platinol AQ or carboplatin Paraplatin, Paraplatin AQ are often added to chemotherapy regimens because research suggests that these drugs may work better against triple-negative and basal-like breast cancers.

Neither hormonal therapy nor targeted therapy is offered for triple-negative or basal-like breast cancer. Immunotherapy may be used to treat locally advanced or metastatic triple-negative breast cancer. Atezolizumab Tecentriq is an immune checkpoint inhibitor used in combination with nab-paclitaxel Abraxane to treat advanced or metastatic triple-negative breast cancer that expresses the PD-L1 protein.

Call us toll-free at Or write us. We will reply by email or phone if you leave us your details. If we are not able to reach you by phone, we will leave a voicemail message. Learn more. Presented in partnership with Desjardins. Select the text below and copy the link.

Triple-negative and basal-like breast cancers Many breast cancer cells have receptors for estrogen or progesterone. Diagnosis When you are diagnosed with breast cancer, your healthcare team will do certain tests to help them develop a treatment plan for you.

Treatments If you have triple-negative or basal-like breast cancer, your healthcare team will create a treatment plan just for you. Radiation therapy is sometimes offered after surgery.

First name:. Last name:. Email address:. Phone Number:. Postal code:. Stories Dr Trang Hoang is targeting resistant cells in childhood leukemia.

Links to help you Publications Talk to an information specialist Talk to someone who's been there Connect with our online community. How can you stop cancer before it starts? Need more information?

Basal cell carcinoma in a breast

Basal cell carcinoma in a breast